{"id":"NCT00445770","sponsor":"Pfizer","briefTitle":"Study Evaluating the Efficacy and Safety of Etanercept and Methotrexate in Japanese Subjects With Rheumatoid Arthritis","officialTitle":"A Randomized, Double-Blind, Multicenter, Comparative Study Evaluating the Efficacy and Safety of Etanercept and Methotrexate in Japanese Subjects With Active Rheumatoid Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-07","primaryCompletion":"2010-07","completion":"2010-07","firstPosted":"2007-03-09","resultsPosted":"2011-08-05","lastUpdate":"2011-08-15"},"enrollment":550,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Arthritis, Rheumatoid"],"interventions":[{"type":"DRUG","name":"Etanercept","otherNames":[]},{"type":"DRUG","name":"Etanercept","otherNames":[]},{"type":"DRUG","name":"Methotrexate","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"EXPERIMENTAL"},{"label":"3","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to examine the effects of etanercept (10 mg and 25 mg) compared with methotrexate (up to 8 mg per week) on the slowing of joint destruction.","primaryOutcome":{"measure":"Change From Baseline in Modified Total Sharp Score (mTSS) at Week 52","timeFrame":"Week 52","effectByArm":[{"arm":"Methotrexate","deltaMin":9.82,"sd":1.16},{"arm":"Etanercept 10 mg","deltaMin":5.19,"sd":0.93},{"arm":"Etanercept 25 mg","deltaMin":3.33,"sd":0.73}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG001 vs OG002","p":"0.2634"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":41,"countries":["Japan"]},"refs":{"pmids":["32735145","30836801"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=0881A1-315&StudyName=Study%20Evaluating%20the%20Efficacy%20and%20Safety%20of%20Etanercept%20and%20Methotrexate%20in%20Japanese%20Subjects%20with%20Rheumatoid%20Arthritis"]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":176},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Pharyngitis","Alanine aminotransferase increased","Aspartate aminotransferase increased"]}}